CHRNB4 and head and neck squamous cell carcinoma: In the present study, integration of the analysis of gene expression, overall survival, cancer-related pathways, and the experiments of CHRNB4 gene editing and drug treatment suggested that CHRNB4 is a promising prognostic biomarker and drug target for smoking HNSCC patients.